Neuroscience company with exciting potential
This brain health software group, specialising in digital products to advance clinical research and patient treatment, has reported a much improved order book and sales piplene. Unfortunately, the current year has suffered from weak sales in previous years and an order cancellation, bringing a sharp fall in the shares. The greatly improved order book will start to deliver results in future years and the expansion of the Company's offering into new markets offers significant potential.
According to the World Health Organisation, disorders of the brain, such as Alzheimer’s disease, Schizophrenia, Parkinson’s, depression and mental illness, are the world’s primary cause of ill health, resulting in higher costs and more hospitalisations than any other disease group.
Early diagnosis of brain illnesses is desirable as it can help to reduce the costs associated with Alzheimer’s disease and dementia.
Cambridge Cognition (AIM: COG) is a highly innovative AIM listed digital health technology company, committed…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article Next article
